title: Intestinal failure-associated liver disease and the use of fish oil-based lipid emulsions.
abstract: Intestinal failure (IF) is caused by the critical reduction of functional gut mass below the minimal amount necessary for adequate digestion and absorption to satisfy body nutrient and fluid requirements for maintenance in adults and growth in children. The advent of parenteral nutrition (PN) resulted in a dramatic improvement in life expectancy of patients suffering IF, but it has its own complications, such as catheter related sepsis. In pediatric patients suffering IF, intraluminal intestinal bacterial overgrowth may cause bacterial translocation and subsequent cholestasis and liver fibrosis. With our current understanding of the genesis of intestinal failure associated liver disease (IFALD), it should be prevented or at least early recognized and treated especially in patients experiencing prematurity and/or sepsis. Targeting harmful cytokine responses can be expected to reduce the severity and frequency of IFALD. In that view, prevention of sepsis, appropriate management of enteral feeding, prevention and treatment of intestinal bacterial overgrowth and the effects of fish oil, as providing omega-3 fatty with anti-inflammatory effects, are promising in avoiding or reversing cholestasis. This chapter aims to review both IF and PN related factors of liver disease with special emphasize on inflammation as cause of liver injury and on the use of fish oil based lipid emulsions as a provision of both alpha-tocopherol (200 g/l of 20% emulsion), as anti-oxidant agent and long-chain PUFAs.
authors.affiliation: Department of Pediatric Gastroenterology, Hepatology and Nutrition, Intestinal Failure Rehabilitation Center, National Reference Centre for Rare Digestive Diseases, Hospital Necker-Enfants Malades, University of Paris-Descartes, Paris, France.
authors.forename: Olivier J
authors.initials: OJ
authors.lastname: Goulet
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D000975:Antioxidants / Q000008:administration & dosage; D002779:Cholestasis / Q000517:prevention & control; D004655:Emulsions; D015525:Fatty Acids, Omega-3; D005395:Fish Oils / Q000008:administration & dosage*; D000069196:Gastrointestinal Microbiome; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007410:Intestinal Diseases / Q000150:complications / Q000517:prevention & control*; D007422:Intestines / Q000187:drug effects / Q000382:microbiology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008107:Liver Diseases / Q000150:complications / Q000517:prevention & control*; D010288:Parenteral Nutrition / Q000379:methods; D024502:alpha-Tocopherol / Q000008:administration & dosage
chemical_list: D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D004655:Emulsions; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; D024502:alpha-Tocopherol